Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.
Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.
Exelixis, Inc. (NASDAQ:EXEL) Q3 2023 Earnings Call Transcript November 1, 2023 Operator: Good day, ladies and gentlemen, and welcome to the Exelixis Third Quarter 2023 Financial Results Conference Call. My name is Gigi, and I’ll be your operator for today. As a reminder, this call is being recorded for replay purposes. I would now like […]
Selpercatinib demonstrated a statistically significant improvement in progression-free survival vs physician’s choice of cabozantinib or vandetanib in patients with advanced or metastatic RET-mutant medullary thyroid cancer, meeting the primary end point of the phase 3 LIBRETTO-531 trial.
The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival compared with a second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer and measurable soft tissue disease following 1 prior novel hormonal therapy, meeting one of the primary end points in the primary analysis of the phase 3 CONTACT-02 trial.